 Precision BioSciences Inc NASDAQ: DTIL and Tiziana Life Sciences plc NASDAQ: TLSA have announced an exclusive license agreement for Tizianas foralumab. The companies plan to explore the fully human anti-CD3 monoclonal antibody as an agent to induce tolerance of allogeneic CAR T cells. 